Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUOFAG for infected surgical wounds
2024-518307-22-01Phase 2Authorised
- Sponsor
- MB Pharma
- Start
- Dec 2024
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in surgical site infection (SSI), Suture rupture (SWD), Staphylococcus aureus infection and 1 more comparing DUOFAG with Placebo (2 arms). Primary endpoints: Frequency of all local and systemic reactions related to investigational product and Time to commencement of healing. Planned start Dec 2024; status: authorised.
02
Drugs
DUOFAG
03
Conditions
surgical site infection (SSI)Suture rupture (SWD)Staphylococcus aureus infectionPseudomonal infection
Beyond the preview
Go deeper on 2024-518307-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518307-22-01.